Sibylle Loibl, MD, PhD, on Adding Durvalumab to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Posted: Wednesday, July 7, 2021

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses the clinical implications of adding durvalumab to neoadjuvant anthracycline therapy for women with triple-negative breast cancer, the rationale for this regimen as well as its toxicities, and next steps in the treatment’s evolution.